Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -42.83% is 17% above its 1-year average of -51.53%, near the high end of its 1-year range (-60.23%–-42.83%).
As of the fiscal period ended Wednesday, December 31, 2025. 16.88% above its 12-month average of -51.53%.
Limited history available
ATTO Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-42.83%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-51.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.88%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.61%
median of 660 covered companies
CURRENT VS SECTOR MEDIAN
-27.41%
vs the sector median at left
Attovia Therapeutics, Inc.
Market Cap
$780.99M
Return on Invested Capital (ROIC)
-42.83%
TTM Avg
-51.53%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$770.72M
Return on Invested Capital (ROIC)
-38.92%
TTM Avg
-31.45%
3Y Avg
-27.82%
5Y Avg
-24.27%
Market Cap
$772.37M
Return on Invested Capital (ROIC)
3.29%
TTM Avg
2.60%
3Y Avg
-15.46%
5Y Avg
-9.88%
Market Cap
$787.65M
Return on Invested Capital (ROIC)
-23.16%
TTM Avg
-53.28%
3Y Avg
-63.06%
5Y Avg
-59.41%
Market Cap
$795.58M
Return on Invested Capital (ROIC)
-0.26%
TTM Avg
4.90%
3Y Avg
-0.53%
5Y Avg
1.15%
Market Cap
$790.35M
Return on Invested Capital (ROIC)
-8.34%
TTM Avg
-22.82%
3Y Avg
-51.67%
5Y Avg
-50.32%
Market Cap
$796.03M
Return on Invested Capital (ROIC)
-9.77%
TTM Avg
8.57%
3Y Avg
-11.39%
5Y Avg
-51.99%
Market Cap
$752.87M
Return on Invested Capital (ROIC)
-36.83%
TTM Avg
-41.75%
3Y Avg
-59.42%
5Y Avg
-51.49%
Market Cap
$805.31M
Return on Invested Capital (ROIC)
9.20%
TTM Avg
13.08%
3Y Avg
19.17%
5Y Avg
23.78%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $780.99M | -42.83% | -51.53% | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $770.72M | -38.92% | -31.45% | -27.82% | -24.27% |
| Mesa Laboratories, Inc. (MLAB)vs › | $772.37M | 3.29% | 2.60% | -15.46% | -9.88% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $787.65M | -23.16% | -53.28% | -63.06% | -59.41% |
| AdaptHealth Corp. (AHCO)vs › | $795.58M | -0.26% | 4.90% | -0.53% | 1.15% |
| Geron Corporation (GERN)vs › | $790.35M | -8.34% | -22.82% | -51.67% | -50.32% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $796.03M | -9.77% | 8.57% | -11.39% | -51.99% |
| Candel Therapeutics, Inc. (CADL)vs › | $752.87M | -36.83% | -41.75% | -59.42% | -51.49% |
| InMode Ltd. (INMD)vs › | $805.31M | 9.20% | 13.08% | 19.17% | 23.78% |
| Apnimed, Inc. (APMD)vs › | $807.61M | N/A | N/A | N/A | N/A |
ROIC
-42.8%
ROE
-40.2%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -42.83% |
| 2024-12-31 | -60.23% |
